5. Dezember 2023

Walder Wyss advised Nasdaq listed Altamira Therapeutics in its sale of a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology. Altamira sold the 51% stake for a cash consideration and will be further entitled to receive 25% of Altamira Medica’s future licensing income. In addition, the transaction included the sale of Auris Medical Pty Ltd, Australia, and a cash contribution to Altamira Medica’s equity by its two shareholders pro rata of their shareholdings.

The Walder Wyss team was led by Alex Nikitine (Partner, Corporate/M&A) and Iliana Djagova (Counsel, Corporate/M&A) and further included Fabienne Limacher (Partner, Tax), Erik Lanz (Associate, Corporate/M&A), Natascha Rizzi (Associate, Tax) and Arbër Hyseni (Trainee Lawyer, Corporate/M&A).